UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Subscribe To Our Newsletter & Stay Updated